K. Pasi

发表

Versatile peptide dendrimers for nucleic acid delivery.

Alexander T Florence, H. Bayele, T. Sakthivel, 2005, Journal of pharmaceutical sciences.

Absence of Inhibitors in Previously Untreated Patients with Severe Haemophilia A after Exposure to a Single Intermediate Purity Factor VIII Product

K. Pasi, T. Yee, C. Lee, 1997, Thrombosis and Haemostasis.

Factor VIII inhibitors in haemophiliacs: a single‐centre experience over 34 years, 1964–97

K. Pasi, T. Yee, C. Lee, 1999, British journal of haematology.

The incidence and magnitude of fibrinolytic activation in trauma patients

S. Stanworth, K. Pasi, K. Brohi, 2013, Journal of thrombosis and haemostasis : JTH.

Haemophilias A and B

K. Pasi, P. Bolton-Maggs, K John Pasi, 2003, The Lancet.

hemophilia A: implications for genetic counseling Analysis of intron 22 inversions of the factor VIII gene in severe

K. Pasi, P. Collins, A. Riddell, 2011 .

Carrier detection and prenatal diagnosis by intron 22 inversion analysis of the factor VIII gene

K. Pasi, P. V. Jenkins, E. Goldman, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Analysis of intron 22 inversions of the factor VIII gene in severe hemophilia A: implications for genetic counseling.

K. Pasi, P. Collins, C. Lee, 1994, Blood.

Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.

H. Ertl, K. Pasi, R. Herzog, 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

Thrombosis and inflammatory bowel disease.

D. Rampton, K. Pasi, P. Irving, 2005, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

The diagnosis of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors’ Organization

M. Laffan, K. Pasi, P. Collins, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

A. Akinc, D. Bevan, K. Pasi, 2017, The New England journal of medicine.

Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran—Results of the phase 1 inhibitor cohort

K. Pasi, T. Lissitchkov, M. Ragni, 2021, Journal of thrombosis and haemostasis : JTH.

Whole genome sequencing of a sporadic primary immunodeficiency cohort

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2018, Nature.

Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19

S. Sivapalaratnam, K. Pasi, D. Hart, 2020, The New England journal of medicine.

In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity

K. Pasi, F. Hill, 1990, British journal of haematology.

Future perspectives in paediatric haemophilia

K. Pasi, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Haemophilia and Von Willebrand Disease

M. Laffan, K. Pasi, 2015 .

41. Inherited Bleeding Disorders

M. Laffan, K. Pasi, 2010 .

Inherited Bleeding Disorders

M. Laffan, K. Pasi, 2007 .

Management of von Willebrand disease: a guideline from the UK Haemophilia Centre Doctors' Organization

G. Dolan, M. Laffan, K. Pasi, 2004, Haemophilia : the official journal of the World Federation of Hemophilia.

Identification of Type 2 von Willebrand Disease in Previously Diagnosed Type 1 Patients: a Reappraisal Using Phenotypes, Genotypes and Molecular Modelling

S. Perkins, K. Pasi, C. Lee, 2000, Thrombosis and Haemostasis.

von Willebrand Factor Activity Detected in a Monoclonal Antibody-based ELISA: an Alternative to the Ristocetin Cofactor Platelet Agglutination Assay for Diagnostic Use

A. Goodall, K. Pasi, B. Woodhams, 1997, Thrombosis and Haemostasis.

Recurrent venous thromboembolic disease and factor XI concentrate in a patient with severe factor XI deficiency, chronic myelomonocytic leukaemia, factor V Leiden and heterozygous plasminogen deficiency.

D. Perry, K. Pasi, C. Lee, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

A framework for genetic service provision for haemophilia and other inherited bleeding disorders

D. Perry, A. Fryer, G. Dolan, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.

M. Ozelo, D. Quon, A. Leavitt, 2022, The New England journal of medicine.

Adeno-associated virus (AAV)–mediated gene therapy is under investigation as a thera- peutic option for persons with hemophilia A. Efficacy and safety data include 3 years of follow-up after a single administration of AAV5-hFVIII-SQ

M. Laffan, K. Pasi, S. Rangarajan, 2019 .

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.

C. Kessler, K. Pasi, S. Courter, 2001, Blood.

Gene therapy for haemophilia

K. Pasi, 2001, Bailliere's clinical haematology.

Activity of Transgene-Produced B-Domain Deleted Factor VIII in Human Plasma Following AAV5 Gene Therapy.

K. Pasi, S. Rangarajan, G. Pierce, 2020, Blood.

Hemophilia gene therapy knowledge and perceptions: Results of an international survey

A. Srivastava, K. Pasi, J. Mahlangu, 2020, Research and practice in thrombosis and haemostasis.

Markers of platelet activation, thrombin generation and fibrinolysis in women with sickle cell disease: effects of differing forms of hormonal contraception

D. Perry, K. Pasi, W. Yoong, 2003, European journal of haematology.

Coagulation status and complications of pregnancy.

K. Pasi, P. Deol, S. Pavord, 2005, Thrombosis research.

Fish as Bioreactors: Transgene Expression of Human Coagulation Factor VII in Fish Embryos

Darren W. Williams, F. Müller, N. Maclean, 2004, Marine Biotechnology.

Thromboembolism and the combined oral contraceptive pill

D. Perry, K. Pasi, C. A. Lee, 1995, The Lancet.

Resistance to activated protein C and factor V Leiden.

D. Perry, K. Pasi, 1997, QJM : monthly journal of the Association of Physicians.

Serological evidence that dry heating of clotting factor concentrates prevents transmission of non‐A, non‐B hepatitis

K. Pasi, F. Hill, S. Mawson, 1990, Journal of medical virology.

Induction of tissue factor expression in human monocyte/endothelium cocultures

A. Hoffbrand, K. Pasi, K. Yong, 1995, British journal of haematology.

Novel cationic lipidic peptide dendrimer vectors in vitro gene delivery

D. Perry, H. Bayele, T. Sakthivel, 1999 .

Residual factor VIII-like cofactor activity of thioredoxin and related oxidoreductases.

H. Bayele, K. Pasi, P. J. Murdock, 2010, Biochimica et biophysica acta.

Bleeding after tonsillectomy in severe von Willebrand's disease

K. Pasi, C. Lee, W. Grant, 1995, The Journal of Laryngology & Otology.

Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A

M. Laffan, K. Pasi, S. Rangarajan, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor VIII Fc for the treatment of haemophilia A

C. Hermans, K. Pasi, M. Mancuso, 2021, European journal of haematology.

Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study

J. Oldenburg, E. Santagostino, B. Konkle, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

The use of enhanced half‐life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

K. Pasi, P. Collins, S. Rangarajan, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

PK‐guided personalized prophylaxis with Nuwiq® (human‐cl rhFVIII) in adults with severe haemophilia A

K. Pasi, R. Klamroth, T. Lissitchkov, 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein (rFIXFc) in subjects with haemophilia B.

J. Oldenburg, D. Perry, M. Ozelo, 2016, Thrombosis and haemostasis.

Long-term safety and efficacy of extended-interval prophylaxis with recombinant factor IX Fc fusion protein ( rFIXFc ) in subjects with haemophilia

J. Oldenburg, D. Perry, M. Ozelo, 2017 .

Clinical haemophilia Long-term safety and efficacy of recombinant factor VIII Fc fusion protein ( rFVIIIFc ) in subjects with haemophilia

D. Perry, B. Konkle, K. Pasi, 2016 .

Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.

J. Dumont, D. Perry, L. Valentino, 2013, The New England journal of medicine.

The safety and efficacy of recombinant human blood coagulation factor IX in previously untreated patients with severe or moderately severe hemophilia B.

V. Blanchette, C. Rothschild, C. Négrier, 2005, Blood.

Use of recombinant factor IX in subjects with haemophilia B undergoing surgery

K. Pasi, M. Ragni, G. White, 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

Recombinant factor VIII Fc fusion protein: extended‐interval dosing maintains low bleeding rates and correlates with von Willebrand factor levels

J. Dumont, I. Nestorov, D. Quon, 2014, Journal of thrombosis and haemostasis : JTH.

Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.

J. Dumont, I. Nestorov, D. Perry, 2014, Blood.

Long‐term safety and sustained efficacy for up to 5 years of treatment with recombinant factor IX Fc fusion protein in subjects with haemophilia B: Results from the B‐YOND extension study

J. Oldenburg, M. Ozelo, H. Chambost, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

Post hoc analysis to evaluate the effect of recombinant factor IX Fc fusion protein (rFIXFc) prophylaxis in adults and adolescents with target joints and hemophilia B

K. Pasi, R. Liesner, N. Jain, 2016 .

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020, The New England journal of medicine.

Factor VIII gene inversions in severe hemophilia A: results of an international consortium study.

F E Preston, P G Mori, S S Sommer, 1995, Blood.

Thrombelastographic evaluation of coagulation in transurethral prostatectomy.

R. Morgan, D. Cox, K. Pasi, 1996, British journal of urology.

Clinical experience of factor XI deficiency: the role of fresh frozen plasma and factor XI concentrate

K. Pasi, P. Collins, C. Lee, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Access to primary dental care for patients with inherited bleeding disorders

K. Pasi, D. Hart, D. Hart, 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

D. Perry, B. Konkle, K. Pasi, 2016, Haemophilia : the official journal of the World Federation of Hemophilia.

hemophilia A Phase 3 study of recombinant factor VIII Fc fusion protein in severe

J. Dumont, I. Nestorov, D. Perry, 2014 .

Predicting the outcomes of using longer‐acting prophylactic factor VIII to treat people with severe hemophilia A: a hypothetical decision analysis

A. Miners, K. Pasi, S. Krishnan, 2016, Journal of thrombosis and haemostasis : JTH.

Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies

M. Ozelo, S. Lethagen, K. Pasi, 2022, Research and practice in thrombosis and haemostasis.

PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA RECEIVING FITUSIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC TARGETING ANTITHROMBIN FOR THE TREATMENT OF HEMOPHILIA

C. Négrier, K. Pasi, T. Lissitchkov, 2020 .

Management of neonates with inherited bleeding disorders – a survey of current UK practice

K. Pasi, R. Liesner, M. Williams, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

Towards a global multidisciplinary consensus framework on haemophilia gene therapy: Report of the 2nd World Federation of Haemophilia Gene Therapy Round Table

A. Weill, T. Sannié, K. Pasi, 2020, Haemophilia : the official journal of the World Federation of Hemophilia.

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

A. Akinc, D. Bevan, K. Pasi, 2015 .

FACTOR VIII INHIBITORS IN HAEMOPHILIAC S. A SINGLE-CENTER EXPERIENCE OVER 34 YEARS

K. Pasi, T. Yee, C. Lee, 1999 .

Transmission of Human Parvovirus B19 by Coagulation Factor Concentrates

K. Pasi, F. Hill, M. D. Williams, 1990, Vox sanguinis.

Fatal postoperative pulmonary embolism in mild haemophilia

K. Pasi, J. Butcher, 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

Extending recombinant factor IX Fc fusion protein dosing interval to 14 or more days in patients with hemophilia B

M. Ozelo, S. Lethagen, K. Pasi, 2018, Research and practice in thrombosis and haemostasis.

Previously untreated patients and recombinant factor VIII concentrate studies.

K. Pasi, 1997, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Diagnostic accuracy study of a factor VIII ELISA for detection of factor VIII antibodies in congenital and acquired haemophilia A

K. Pasi, P. Batty, D. Hart, 2015, Thrombosis and Haemostasis.

Pre‐analytical heat treatment and a FVIII ELISA improve Factor VIII antibody detection in acquired haemophilia A

K. Pasi, P. Batty, D. Hart, 2014, British journal of haematology.

A survey of patients with acquired haemophilia in a haemophilia centre over a 28-year period.

K. Pasi, A. Taher, T. Yee, 2000, Clinical and laboratory haematology.

Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A

S. Bunting, K. Pasi, S. Fong, 2022, Nature Medicine.

ASPIRE Final Results Confirm Established Safety and Sustained Efficacy for Up to 4 Years of Treatment With rFVIIIFc in Previously Treated Subjects With Severe Hemophilia A

J. Oldenburg, B. Konkle, K. Pasi, 2018, Blood.

Safety trial of heated factor VIII concentrate (8Y).

K. Pasi, F. Hill, 1989, Archives of disease in childhood.

Perioperative Management in Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

C. Négrier, K. Pasi, T. Lissitchkov, 2017 .

Identification and eradication of Helicobacter pylori infection in haemophilic patients

R. Pounder, K. Pasi, C. Lee, 1997, Haemophilia : the official journal of the World Federation of Hemophilia.

A Subcutaneously Administered Investigational RNAi Therapeutic, Fitusiran (ALN-AT3), Targeting Antithrombin for Treatment of Hemophilia: Interim Results in Patients with Hemophilia A or B

Creagh, A. Akinc, D. Bevan, 2016 .

Life-threatening human parvovirus B19 infection in immunocompetent haemophilia

Christine A. Lee, K. Pasi, T. Yee, 1995, The Lancet.

Safety and efficacy of a von Willebrand factor/factor VIII concentrate (Wilate®): a single centre experience

K. Pasi, P. Batty, D. Hart, 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

Gene therapy trials for haemophilia: a step closer to a cure?

K. Pasi, P. Batty, 2019, Expert Review of Precision Medicine and Drug Development.

Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.

M. Laffan, K. Pasi, S. Rangarajan, 2020 .

B-YOND Final Results Confirm Established Safety, Sustained Efficacy, and Extended Dosing Interval for Up to 4 Years of Treatment With rFIXFc in Previously Treated Subjects With Severe Hemophilia B

J. Oldenburg, K. Pasi, K. Fischer, 2018, Blood.

Evolution of haemophilia integrated care in the era of gene therapy: Treatment centre’s readiness in United States and EU

C. Hermans, K. Pasi, M. Skinner, 2021, Haemophilia : the official journal of the World Federation of Hemophilia.

Gene therapy trials in the UK: is haemophilia a suitable 'model'?

D. Perry, G. Dolan, K. Pasi, 2004, Clinical medicine.

Functional definition and characterization of acute traumatic coagulopathy

Karim Brohi, Rupert Pearse, Daniel Hart, 2011, Critical care medicine.

Long-Term Safety and Efficacy of rFVIIIFc in Adults and Adolescents with Severe Hemophilia A: A Longitudinal Analysis of A-LONG and ASPIRE

D. Perry, B. Konkle, K. Pasi, 2015 .

A FIRST-IN-HUMAN FOUR-YEAR FOLLOW-UP STUDY OF DURABLE THERAPEUTIC EFFICACY AND SAFETY OF AAV GENE THERAPY WITH VALOCTOCOGENE ROXAPARVOVEC FOR SEVERE HEMOPHILIA A

M. Ozelo, M. Laffan, K. Pasi, 2020 .

7 Gene therapy for haemophilia

K. Pasi, 1996 .

Transmission of symptomatic parvovirus B19 infection by clotting factor concentrate

K. Pasi, T. Yee, C. Lee, 1996, British journal of haematology.

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A. Akinc, D. Bevan, K. Pasi, 2016 .

Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood‐borne virus infection

M. Wadhwa, R. Thorpe, K. Pasi, 1995, British journal of haematology.

Molecular modeling of ligand and mutation sites of the type A domains of human von Willebrand factor and their relevance to von Willebrand's disease.

S. Perkins, K. Pasi, P. V. Jenkins, 1998, Blood.

Whole-genome sequencing of a sporadic primary immunodeficiency cohort

William J. Astle, Sri V. V. Deevi, Kenneth G. C. Smith, 2020, Nature.

Aberrant dimerization of von Willebrand factor as the result of mutations in the carboxy-terminal region: identification of 3 mutations in members of 3 different families with type 2A (phenotype IID) von Willebrand disease.

K. Pasi, F. Hill, M. D. Williams, 2001, Blood.

Thromboelastography: An effective screening test for prothrombotic states

D. Perry, K. Pasi, G. Hamilton, 1998 .

Follow up study in the assessment of rVlla as a universal haemostatic agent in a model of haemodilution

K. Pasi, S. Chillala, PA Evans, 2002, Critical Care.

The effects of the 32‐bp CCR‐5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia

C. Sabin, K. Pasi, C. Lee, 2000, British journal of haematology.

Clinical and laboratory evaluation of the treatment of von Willebrand's disease patients with heat‐treated factor VIII concentrate (BPL 8Y)

K. Pasi, F. Hill, M. Williams, 1990, British journal of haematology.

Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.

R. Dolmetsch, J. Astermark, C. Hermans, 2023, The New England journal of medicine.

Successful long‐term treatment with porcine factor VIII of a patient with haemophilia A and an inhibitor to factor VIII

K. Pasi, C. Lee, P. Vyas, 1996, Haemophilia : the official journal of the World Federation of Hemophilia.

The effects of the 32-bp CCR-5 deletion on HIV transmission and HIV disease progression in individuals with haemophilia.

C. Sabin, K. Pasi, C. Lee, 2000 .

Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV postive men with haemophilia A

C. Sabin, Christine A. Lee, A. Phillips, 1996, BMJ.

Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)

K. Pasi, F. Hill, J. A. Evans, 1991, British journal of haematology.

Hemostasis : components and processes.

K. Pasi, 1999, Methods in molecular medicine.

Qualitative and quantitative abnormalities of von Willebrand antigen in patients with diabetes mellitus.

K. Pasi, A. Wright, F. Hill, 1990, Thrombosis research.

Type 2M vWD Resulting from a Lysine Deletion within a Four Lysine Residue Repeat in the A1 Loop of von Willebrand Factor

K. Pasi, P. Collins, C. Mazurier, 2000, Thrombosis and Haemostasis.

Molecular analysis of the genotype-phenotype relationship in factor X deficiency

D. Cooper, M. Krawczak, A. Wacey, 2000, Human Genetics.

Simple shifts in redox/thiol balance that perturb blood coagulation

H. Bayele, K. Pasi, D. Perry, 2002, FEBS letters.

Factor VIII-von Willebrand factor in haemolytic uraemic syndrome.

K. Pasi, M. Enayat, 1989, BMJ.

Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centres

K. Pasi, P. Batty, D. Hart, 2015, Haemophilia : the official journal of the World Federation of Hemophilia.

Effect of nifedipine on glucose tolerance, serum insulin, and serum fructosamine in diabetic and nondiabetic patients.

K. Pasi, D. Beevers, J. Gill, 1987, Clinical therapeutics.

Hemostasis and thrombosis protocols

David J. Perry, D. Perry, K. Pasi, 1999 .

Growth in haemophilic boys after HIV infection.

K. Pasi, F. Hill, A. Ewer, 1990, Archives of disease in childhood.

Acquired haemophilia, an unusual cause of severe postpartum haemorrhage

K. Pasi, C. Lee, R. Kadir, 1997, British journal of obstetrics and gynaecology.

De novo mutation causing sporadic type 2A von Willebrancd's disease: report of three cases

K. Pasi, F. Hill, B. Theophilus, 1996, Haemophilia.

Expression of factor VII by muscle cells in vitro and in vivo following direct gene transfer: modelling gene therapy for haemophilia.

R. Steinbrecher, K. Pasi, G. Miller, 1995, Gene therapy.

Intron 22 Inversions and haemophilia

M. Baiget, E. Tizzano, R. Ljung, 1994, The Lancet.

FACTOR VIII AND IX INHIBITORS AFTER EXPOSURE TO HEAT-TREATED CONCENTRATES

D. Perry, K. Pasi, M. Hamon, 1987, The Lancet.

Long-Term Efficacy and Quality of Life with Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) Prophylaxis in Pediatric, Adolescent, and Adult Subjects with Target Joints and Severe Hemophilia a

B. Kerlin, Michael Wang, S. Lethagen, 2016 .

Lupus Anticoagulant in Patients with Covid-19. Reply.

K. Pasi, S. Platton, L. Bowles, 2020, New England Journal of Medicine.

Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a

D. Perry, K. Pasi, S. Rangarajan, 2017 .

EXPRESSION OF FACTOR-VII IN-VITRO AND IN-VIVO FOLLOWING DIRECT GENE-TRANSFER INTO MUSCLE - A MODEL FOR HEMOPHILIA

R. Steinbrecher, K. Pasi, G. Miller, 1995 .

Gene therapy for haemophilia

K. Pasi, Akshay Sharma, U. Reiss, 2001, British journal of haematology.

Evidence for the aetiological role of blood‐borne virus infections in causing reduced lectin‐induced T‐cell proliferation in haemophilic boys

K. Pasi, F. Hill, J. A. Evans, 1995, British Journal of Haematology.

Cytolytic activity against mycobacterial antigens: differences between haemophiliacs with and without HIV infection

K. Pasi, F. Hill, J. A. Evans, 1995, Haemophilia : the official journal of the World Federation of Hemophilia.

Von Willebrand's disease -- awareness influences diagnosis.

K. Pasi, 2005, The Indian journal of medical research.